PATENT CLAIM ANALYSIS

Application Number: 16094644
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["424", "470000"]

Abstract:
Described herein are pharmaceutical compositions for the oral administration of mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of mesalazine.

Claim (Index 51):
The unit dose pharmaceutical product of  claim 42 , wherein, when subject to in vitro dissolution testing according to USP Type 1 Basket at 37\u00b0 C. and 100 rpm in 500 mL dissolution medium of pH 1.2 buffer for 2 hours, followed by pH 4.5 buffer for 2 hours, followed by pH 7.0 buffer for 12 hours, the delayed-extended release minitablets exhibit substantially no release of mesalazine at pH 1.2 and pH 4.5, and exhibit extended release of mesalazine over at least 8 hours at pH 7.0.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.46429
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15076253', '14255529', '14589839', '14230067', '14841428']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7582554474810601
- 35 USC 102 Novelty (BERT): 0.5204387743328265
- Combined Prediction Score: 0.7344737801662368
- Mean Citation Score: 313.1899160000001
- Max Citation Score: 319.44415
- Similarity Product: 230.52039852814084

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test